文献速递艾滋病与性传播感染病毒性肝炎

非酒精性脂肪性肝病及伴肝纤维化的非酒精性脂肪性肝炎可预测HIV感染者新发糖尿病:一项纵向队列研究

Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis With Liver Fibrosis as Predictors of New-Onset Diabetes Mellitus in People With HIV: A Longitudinal Cohort Study.
PubMed 文献 · Clin Infect Dis · 2023-01-01

这项前瞻性研究纳入847例无过量饮酒或肝炎合并感染的HIV感染者,基线NAFLD与新发糖尿病风险升高2.8倍相关,NAFLD合并NASH则升高3.1倍;基线糖尿病不预测NAFLD或NASH进展,但替诺福韦艾拉酚胺使用与NAFLD及NASH发生风险升高相关。

要点

  • 基线NAFLD与新发糖尿病风险升高2.8倍相关。
  • 基线NAFLD合并NASH与新发糖尿病风险升高3.1倍相关。
  • 替诺福韦艾拉酚胺使用与NAFLD发生(HR 2.01)及NASH发生(HR 2.31)风险升高相关。

核心结论

  • NAFLD单独或合并NASH均强烈预测新发糖尿病,这凸显了对NAFLD/NASH进行系统风险评估和管理的必要性,因其可能促成HIV感染者的代谢并发症如糖尿病及后续心血管疾病。

研究设计与样本

  • 前瞻性研究,分析847例年龄≥18岁、无过量饮酒或肝炎合并感染的HIV感染者。
  • NAFLD定义为受控衰减参数≥248 dB/m,伴显著疾病活动度和肝纤维化的NASH定义为FibroScan-AST评分≥0.67。
  • 采用Cox比例风险回归探讨NAFLD伴或不伴NASH与新发糖尿病之间的关联。

主要发现

  • 847例HIV感染者基线中位年龄45岁(四分位距38-51),女性占43%。
  • 调整年龄、性别、糖尿病家族史、抗逆转录病毒治疗时长、吸烟、他汀使用、司他夫定/去羟肌苷/齐多夫定暴露、时变体重指数、高血压和血脂异常后,基线NAFLD与新发糖尿病风险升高2.8倍相关。
  • 基线NAFLD合并NASH与新发糖尿病风险升高3.1倍相关。
  • 在单独分析中,基线糖尿病不预测NAFLD或NASH进展,但替诺福韦艾拉酚胺使用与NAFLD发生风险升高相关(HR 2.01;95%CI 1.02-4.02),也与NASH发生风险升高相关(HR 2.31;95%CI 1.12-5.11)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We investigated the association between nonalcoholic fatty liver disease (NAFLD) plus or minus a concurrent diagnosis of nonalcoholic steatohepatitis (NASH) and incident diabetes mellitus (DM) and the risk factors associated with NAFLD or NASH development. METHODS: In this prospective study, we analyzed people with human immunodeficiency virus (HIV; PWH) aged ≥18 years without excessive alcohol consumption or hepatitis coinfections. NAFLD was defined as controlled attenuation parameter ≥248 dB/m, whereas NASH with significant disease activity and liver fibrosis was defined as a FibroScan-AST score ≥0.67. Cox proportional hazard regression was used to investigate the association between NAFLD with or without NASH and new-onset DM. RESULTS: Of 847 PWH, the median age at baseline was 45 years (interquartile range, 38-51; 43% female). Baseline NAFLD was associated with 2.8-fold higher risk of new-onset DM after adjusting for age, sex, family history of DM, antiretroviral therapy duration, smoking, statin use, stavudine/didanosine/zidovudine exposure, time-updated body mass index, hypertension, and dyslipidemia. Combined NAFLD and NASH at baseline had 3.1-fold higher new-onset DM risk. In separate analyses, baseline DM did not predict progression to NAFLD or NASH, but tenofovir alafenamide use was associated with an increased risk of NAFLD (hazard ratio [HR], 2.01; 95% confidence interval [CI], 1.02-4.02) or NASH development (2.31; 95% CI, 1.12-5.11). CONCLUSIONS: NAFLD alone or combined with NASH strongly predicts new-onset DM. This highlights the need for systematic risk assessments and management of NAFLD/NASH, as it may contribute to metabolic complications such as DM and subsequent cardiovascular diseases in PWH.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Han WM, Apornpong T, Lwin HMS, et al. Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis With Liver Fibrosis as Predictors of New-Onset Diabetes Mellitus in People With HIV: A Longitudinal Cohort Study. Clin Infect Dis. 2023. PMID: 37477514. doi:10.1093/cid/ciad433

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。